Crestone’s CRS3123 Shows Superior Efficacy in Curing C. difficile Infections and Preventing Recurrence Compared to Vancomycin in Phase 2 Trial

Clinical Cure Rate:
CRS3123 achieved a 97% clinical cure rate at the day 12 test-of-cure visit, compared to 93% in the vancomycin group.

Recurrence Rates:
Patients treated with CRS3123 had significantly lower recurrence rates (4%) compared to those treated with vancomycin (23%) at day 40.

Mechanism of Action:
CRS3123 selectively inhibits methionyl-tRNA synthetase, a novel target that is not affected by resistance to existing classes of antibiotics.

Minimal Disruption:
CRS3123 has a narrow spectrum and minimal disruption of normal gut microbiota, which is crucial for preventing further recurrences of CDI.

Funding and Support:
The National Institute of Allergy and Infectious Diseases (NIAID) provided additional funding of $4.5 million for further development, including microbiome analyses and manufacturing process optimization.

Future Plans:
Crestone plans to discuss the results with the FDA and prospective development partners to accelerate into pivotal CDI studies with CRS3123.